Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis

Table 2

Effect in vivo of natural and synthetic jasmonates derivatives.

Jasmonates	Conc. range/vehicle	Organism/tissue/cells	Effects	References
MJ (oral)	236 mg/kg/lipofundin	Normal C57BL/6 mice	Nontoxic	[15]
MJ (oral)	236 mg/kg/lipofundin	C57BL/6 mice injected i.p. with murine T-lymphoma EL-4	↑survival of treated mice as compared to the inoculated control	[15]
TBrJA	40 μM/EtOH; (lower doses than MJ in vitro)	Murine melanoma; B16-F10	↓lung metastasis	[39]
MJ	1–10 μM/EtOH	Chicken CAM	↓angiogenesis	[40]
MJ	1–10 μM/EtOH	Human endothelial cells (HUVEC)	↓COX-2/PGE2 pathway	[40]
MJ (i.p.)	1 g/kg in 0.1 mL vegetal oil, i.p.	Multiple myeloma- (MM.1S-) inoculated; in nod/scid mice	↑survival of treated mice as compared to the inoculated control	[105]
MJ (topical)	1 g/mL oil	Application on cancerous and precancerous human skin lesions	No local or systemic side effects; 3/8 patients with; positive responses	[51]

CAM:chorioallantoic membrane of chicken embryo; HUVEC: human umbilical vein and endothelial cells; TBrJA: synthetic 5, 7, 9, 10-tetrabromo jasmonate.